Genomic and Molecular Screenings Identify Different Mechanisms for Acquired Resistance to MET Inhibitors in Lung Cancer Cells
作者： Pol Gimenez-Xavier , Eva Pros , Ester Bonastre , Sebastian Moran , Ana Aza
DOI: 10.1158/1535-7163.MCT-17-0104
关键词: Molecular biology 、 Lung cancer 、 DNA methylation 、 Gene 、 PI3K/AKT/mTOR pathway 、 Regulation of gene expression 、 Biology 、 Erlotinib 、 Gene expression 、 Tyrosine kinase
摘要: The development of resistance to tyrosine kinase inhibitors (TKI) limits the long-term efficacy cancer treatments involving them. We aimed understand mechanisms that underlie acquired (AR) MET in lung cancer. EBC1 cells, which have amplification and are sensitive TKIs against MET, were used generate multiple clones with AR a MET-TKI. Whole-exome sequencing, RNA global DNA methylation analysis scrutinize genetic molecular characteristics resistant cells. MET-TKI involved changes common all is, phenotypic modifications, specific gene expression, reactivation AKT, ERK, mTOR. methylation, mutational profiles distinguished at least two groups In one these, cells sensitivity erlotinib, concomitantly mutations KIRREL, HDAC11, HIATL1, MAPK1IP1L genes, among others. other group, some inactivation neurofibromatosis type 2 (NF2) strong overexpression NRG1 profile includes LMLN TOMM34 Multiple independent simultaneous strategies lead MET-TKIs erlotinib supports known crosstalk between HER family receptors. For first time, we show NF2 during acquisition may explain refractoriness these Mol Cancer Ther; 16(7); 1366-76. ©2017 AACR.
aacrjournals.org
sci-hub.se 参考文章(42)
Trevor N Stitt, Greg Conn, Martin Goret, Cary Lai, Joanne Bruno, Czeslaw Radzlejewski, Karen Mattsson, John Fisher, David R Gies, Pamela F Jones, Piotr Masiakowski, Terence E Ryan, Nancy J Tobkes, D.H Chen, Peter S DiStefano, George L Long, Claudio Basilico, Mitchell P Goldfarb, Greg Lemke, David J Glass, George D Yancopoulos, The anticoagulation factor protein S and its relative, Gas6, are ligands for the Tyro 3/Axl family of receptor tyrosine kinases Cell. ,vol. 80, pp. 661- 670 ,(1995) , 10.1016/0092-8674(95)90520-0
L. V. Sequist, B. A. Waltman, D. Dias-Santagata, S. Digumarthy, A. B. Turke, P. Fidias, K. Bergethon, A. T. Shaw, S. Gettinger, A. K. Cosper, S. Akhavanfard, R. S. Heist, J. Temel, J. G. Christensen, J. C. Wain, T. J. Lynch, K. Vernovsky, E. J. Mark, M. Lanuti, A. J. Iafrate, M. Mino-Kenudson, J. A. Engelman, Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors Science Translational Medicine. ,vol. 3, ,(2011) , 10.1126/SCITRANSLMED.3002003
Zhenfeng Zhang, Jae Cheol Lee, Luping Lin, Victor Olivas, Valerie Au, Thomas LaFramboise, Mohamed Abdel-Rahman, Xiaoqi Wang, Alan D Levine, Jin Kyung Rho, Yun Jung Choi, Chang-Min Choi, Sang-We Kim, Se Jin Jang, Young Soo Park, Woo Sung Kim, Dae Ho Lee, Jung-Shin Lee, Vincent A Miller, Maria Arcila, Marc Ladanyi, Philicia Moonsamy, Charles Sawyers, Titus J Boggon, Patrick C Ma, Carlota Costa, Miquel Taron, Rafael Rosell, Balazs Halmos, Trever G Bivona, Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer Nature Genetics. ,vol. 44, pp. 852- 860 ,(2012) , 10.1038/NG.2330
Alexa B. Turke, Kreshnik Zejnullahu, Yi-Long Wu, Youngchul Song, Dora Dias-Santagata, Eugene Lifshits, Luca Toschi, Andrew Rogers, Tony Mok, Lecia Sequist, Neal I. Lindeman, Carly Murphy, Sara Akhavanfard, Beow Y. Yeap, Yun Xiao, Marzia Capelletti, A. John Iafrate, Charles Lee, James G. Christensen, Jeffrey A. Engelman, Pasi A. Jänne, Preexistence and Clonal Selection of MET Amplification in EGFR Mutant NSCLC Cancer Cell. ,vol. 17, pp. 77- 88 ,(2010) , 10.1016/J.CCR.2009.11.022
Valentina Pirazzoli, Caroline Nebhan, Xiaoling Song, Anna Wurtz, Zenta Walther, Guoping Cai, Zhongming Zhao, Peilin Jia, Elisa de Stanchina, Erik M Shapiro, Molly Gale, Ruonan Yin, Leora Horn, David P Carbone, Philip J Stephens, Vincent Miller, Scott Gettinger, William Pao, Katerina Politi, None, Acquired resistance of EGFR-mutant lung adenocarcinomas to afatinib plus cetuximab is associated with activation of mTORC1 Cell Reports. ,vol. 7, pp. 999- 1008 ,(2014) , 10.1016/J.CELREP.2014.04.014
Kenichi Suda, Hiroshi Mizuuchi, Yoshihiko Maehara, Tetsuya Mitsudomi, Acquired resistance mechanisms to tyrosine kinase inhibitors in lung cancer with activating epidermal growth factor receptor mutation—diversity, ductility, and destiny Cancer and Metastasis Reviews. ,vol. 31, pp. 807- 814 ,(2012) , 10.1007/S10555-012-9391-7
D. Ross Camidge, William Pao, Lecia V. Sequist, Acquired resistance to TKIs in solid tumours: learning from lung cancer Nature Reviews Clinical Oncology. ,vol. 11, pp. 473- 481 ,(2014) , 10.1038/NRCLINONC.2014.104
C Thaxton, J Lopera, M Bott, C Fernandez-Valle, Neuregulin and laminin stimulate phosphorylation of the NF2 tumor suppressor in Schwann cells by distinct protein kinase A and p21-activated kinase-dependent pathways. Oncogene. ,vol. 27, pp. 2705- 2715 ,(2008) , 10.1038/SJ.ONC.1210923
J. A. Engelman, K. Zejnullahu, T. Mitsudomi, Y. Song, C. Hyland, J. O. Park, N. Lindeman, C.-M. Gale, X. Zhao, J. Christensen, T. Kosaka, A. J. Holmes, A. M. Rogers, F. Cappuzzo, T. Mok, C. Lee, B. E. Johnson, L. C. Cantley, P. A. Janne, MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling Science. ,vol. 316, pp. 1039- 1043 ,(2007) , 10.1126/SCIENCE.1141478
William Pao, Vincent A Miller, Katerina A Politi, Gregory J Riely, Romel Somwar, Maureen F Zakowski, Mark G Kris, Harold Varmus, Acquired Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib Is Associated with a Second Mutation in the EGFR Kinase Domain PLoS Medicine. ,vol. 2, pp. e73- ,(2005) , 10.1371/JOURNAL.PMED.0020073